Core Insights - Fiserv, Inc. (FISV) reported mixed fourth-quarter 2025 results, with earnings exceeding expectations while revenues fell short [1] Financial Performance - Adjusted earnings per share were $1.99, surpassing the Zacks Consensus Estimate by 4.7%, but down 20.7% year over year [1] - Adjusted revenues totaled $4.9 billion, missing the consensus estimate by 1% and declining 6.7% year over year [1] - Processing and services revenues were $4.3 billion, slightly down year over year but meeting the consensus estimate [3] - Product segment revenues reached $1 billion, up 3.6% from the previous year and beating the consensus estimate of $999.6 million [3] - Merchant solutions generated $2.5 billion in adjusted revenues, a 1.5% year-over-year increase, but missed the consensus mark of $2.6 billion [4] - Financial solutions segment reported adjusted revenues of $2.4 billion, a 1.6% decrease year over year, but met the Zacks Consensus Estimate [5] - Operating income was $816 million, down 1.6% year over year, missing the consensus estimate of $833.9 million [4] Balance Sheet & Cash Flow - Fiserv ended the fourth quarter with cash and cash equivalents of $798 million, down from $1.1 billion in the third quarter [6] - Long-term debt decreased to $27.8 billion from $28.9 billion in the previous quarter [6] - The company generated $1.9 billion in net cash from operating activities and reported free cash flow of $1.6 billion, with capital expenditure at $442 million [6] 2026 Guidance - For 2026, management anticipates organic revenue growth of 1-3% and expects EPS in the range of $8-$8.3, with the midpoint of $8.15 exceeding the consensus mark of $8.12 [7]

Core Insights - AbbVie experienced a sales growth of approximately 8.5% year over year in 2025, despite facing biosimilar erosion of its flagship drug Humira, which lost exclusivity in early 2023 [2] - For 2026, AbbVie projects revenues to reach $67 billion, indicating a growth of about 9.5% over 2025, primarily driven by newer immunology drugs Rinvoq and Skyrizi [3][10] Immunology Segment - AbbVie expects to generate over $31 billion from sales of Skyrizi and Rinvoq in 2026, with both drugs anticipated to grow more than 20% year over year [4][5][10] - Skyrizi is projected to achieve sales of approximately $21.5 billion, while Rinvoq is expected to reach around $10.1 billion [5] Neuroscience Segment - The neuroscience franchise is expected to contribute $12.5 billion in sales for 2026, reflecting a 16% growth over 2025 [7][10] - AbbVie anticipates Vyalev, a new Parkinson's disease therapy, to surpass $1 billion in global sales [7][10] - The company is also seeking FDA approval for a new oral therapy for Parkinson's disease, tavapadon, which could further enhance its neuroscience portfolio [8] Oncology Segment - AbbVie faces near-term challenges in its oncology segment, particularly with the J&J-partnered Imbruvica, which is expected to see sales decline to $2.2 billion, a drop of over 23% from 2025 [11][12][10] - Despite this decline, other oncology drugs are expected to partially offset the impact, including Venclexta, Epkinly, Elahere, and Emrelis [12] Valuation and Market Performance - AbbVie shares have underperformed the industry over the past year and are currently trading at a P/E ratio of 15.25, below the industry average of 18.75 [13][14] - The bottom-line estimate per share for 2026 and 2027 has seen a decline in the past 30 days [16]

Core Insights - Bonk, Inc. has reported strong performance data for January 2026, indicating continued growth from a successful fourth quarter [1] Financial Performance - The reconciled net revenue for January 2026 is $2,464,116, which shows a significant increase from December 2025's revenue of $1.47 million [1] - This represents a month-over-month growth rate of approximately 68%, highlighting the high-margin nature of Bonk, Inc.'s revenue stream [1] - Third-party aggregators initially reported a total platform income of about $5.14 million for January, but Bonk, Inc. has reconciled this figure to reflect actual cash flow received [1]

Core Insights - AstraZeneca PLC demonstrated strong operational performance in a challenging comparison period, with a commitment to long-term growth [1] - The company reported fourth-quarter revenue of $15.5 billion, exceeding consensus by just over 1% [1] Financial Performance - Core earnings per share were $2.12, with underlying earnings growth estimated at 16% for the year after excluding non-repeating collaboration revenue [2] - Oncology sales increased by 19% to $6.47 billion, driven by strong contributions from Imfinzi and Calquence [2] - Cardiovascular, renal, and metabolism (CVRM) sales also exceeded forecasts, although Farxiga is expected to face generic competition starting in Q2 2026 [3] Expenses and Profitability - Core operating profit fell short of consensus by 8% due to higher-than-expected R&D and SG&A expenses, with R&D accounting for 24% of total revenue [4] - The company is investing in late-stage trials and next-generation technologies, including GLP-1s and bispecifics [4] Future Guidance - AstraZeneca provided guidance for mid- to high-single-digit revenue growth in 2026 and low double-digit EPS growth, both at constant exchange rates [4] - ShoreCap's forecast for 2026 includes 11% revenue growth and 19% EPS growth, which may be revised due to higher finance costs [5] Long-term Ambitions - AstraZeneca aims to achieve $80 billion in annual revenue by 2030, with projections suggesting this target may be beatable at $82 billion [5] Valuation - The stock trades at a forward price-to-earnings ratio of 18–19 times for 2026, a premium to peers, justified by a strong pipeline and multiple phase III catalysts expected [6] - Following a sluggish start, shares increased by 1% to 14,044p [6]

ATTIKI, GREECE / ACCESS Newswire / February 9, 2026 / Elvictor Group Inc. (OTC:ELVG) ("Elvictor" or the "Company"), a leader in maritime recruitment and crew management, today announced the expansion of its crew management portfolio following the award of multiple new crewing contracts driven by fleet growth among existing clients. Based on current fee structures, the Company estimates incremental monthly revenue from these contract awards of approximately $140,000, representing annualized revenue of approx ...

Core Insights - Bank of the James Financial Group, Inc. (BOTJ) has shown strong stock performance, gaining 2.1% since its fourth-quarter 2025 earnings report, significantly outperforming the S&P 500 Index, which declined by 0.2% during the same period [1] Financial Performance - For Q4 2025, BOTJ reported a net income of $2.72 million, a 68.3% increase from $1.62 million in Q4 2024, with earnings per share rising to 60 cents from 36 cents [2] - Full-year 2025 net income reached a record $9.02 million, up 13.6% from $7.94 million in 2024, while full-year EPS improved to $1.99 from $1.75, also reflecting a 13.6% gain [2] Revenue and Income Growth - Net interest income for Q4 increased by 11.1% year over year to $8.54 million, and for the full year, it climbed 12.2% to $32.81 million [3] - Total noninterest income rose by 13.3% in Q4 and 4.7% for the full year, indicating growth across various fee-based categories [3] Balance Sheet Metrics - Total assets grew by 6.1% year over year to $1.04 billion as of December 31, 2025, with loans net of allowance for credit losses increasing by 3.9% to $661.36 million [4] - Total deposits rose by 6.2% to $937.13 million, primarily driven by a 7.7% increase in core deposits [4] - Stockholders' equity increased by 23.4% to $80.05 million, supported by retained earnings growth and improved valuations in available-for-sale securities [4] Profitability Metrics - Book value per share increased to $17.62 from $14.28 a year earlier [5] - Return on average assets improved to 1.04% for Q4 compared to 0.63% a year ago, while return on average equity rose to 13.89% from 9.39% [5] Management Commentary - Management emphasized revenue momentum and expense discipline as key drivers of improved results, with margin improvement attributed to active management of deposit pricing and loan yields [6] - The retirement of approximately $10.05 million in capital notes earlier in the year contributed to a decline in interest expense [6] - Ongoing savings from vendor renegotiations and lower professional fees are expected to continue into 2026 [6] Factors Influencing Financial Results - The improved net interest income was supported by an expanded net interest margin of 3.44% in Q4, up from 3.18% a year earlier [7] - Interest expense declined by 12.1% in Q4 and 10.1% for the full year, reflecting lower deposit costs and the retirement of capital notes [7] - Noninterest income growth was primarily driven by gains on loan sales, higher wealth management fees, and increased service charges [7] Expense Management - Noninterest expense decreased by 4.2% year over year in Q4 due to lower data processing costs and reduced professional fees, although full-year noninterest expense rose by 7% due to higher salaries and investments in new banking facilities [8] Strategic Focus - The company is focused on pricing, cost control, and credit discipline, with expense savings from vendor negotiations and process improvements expected to persist [10][11]

Zoetis (NYSE: ZTS) tanked after its November earnings release. Will history repeat itself pre-market on Feb. 12, when the animal healthcare company releases results for the fourth quarter of 2025? That's the question on the minds of many investors, less than a week before its earnings report hits the street. Whether the stock rallies after earnings or falls further afterward may depend on how closely the guidance updates align with current expectations. Fortunately for Zoetis, with expectations already wa ...

Accretive Transaction with Combined Companies’ Pro-Forma Revenue in Excess of $70.00 Million and EBITDA(1) in Excess of $15.75 Million (TTM Sept 30, 2025) MISSISSAUGA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) announced today that it has entered into a Share Purchase Agreement (“SPA”) dated February 8, 2026 to acquire Oral Science Inc. (“Oral Science”), a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral he ...

Core Insights - Ubiquiti Inc. has demonstrated strong financial performance, with impressive earnings and revenue growth in its recent reports [2][3][6] Financial Performance - The company reported earnings of $3.88 per share for the second quarter of fiscal 2026, exceeding the Zacks Consensus Estimate of $2.81 per share by 38.08% [2][6] - Revenue for the same quarter reached $814.87 million, surpassing expectations by 13.18% and showing significant growth from $599.88 million in the previous year [3][6] Stock Performance - Ubiquiti's stock is currently priced at $622.33, reflecting an increase of 8.04% or $46.33 [4] - The stock has experienced volatility, with a yearly high of $803.60 and a low of $255 [4] Dividend Announcement - The Board of Directors has declared a cash dividend of $0.80 per share, payable on February 23, 2026, to shareholders recorded as of February 17, 2026 [5]

Core Insights - Philip Morris International Inc. (PM) reported a strong performance in Q4 2025, with both net sales and earnings showing year-over-year growth, although net sales fell short of expectations while earnings exceeded them [1][3]. Financial Performance - Adjusted earnings for Q4 2025 were $1.70, reflecting a 9.7% increase year-over-year, and beating the Zacks Consensus Estimate of $1.67 [3]. - Net revenues reached $10,362 million, marking a 6.8% increase on a reported basis and a 3.7% increase on an organic basis, although this was below the Zacks Consensus Estimate of $10,428 million [4]. - The adjusted operating income rose 5.8% to $3,722 million, driven by improved pricing and a positive volume/mix, despite increased costs in marketing, administration, and research [6]. Business Segments - Revenues from smoke-free products increased by 12% (8.6% organically), contributing over 50% of net revenues in three of the four regions [5]. - Net revenues from combustible products grew 3.2% year-over-year, with a 0.3% organic increase [5]. Regional Performance - In the European region, net revenues grew 11% (5.1% organically) to $4,598 million, supported by positive pricing and volume/mix, despite lower cigarette volumes [7]. - The SSEA, CIS & MEA regions saw net revenues increase by 8.4% (6.5% organically) to $3,109 million, primarily due to favorable pricing [8]. - In the EA, AU & PMI GTR regions, net revenues fell 0.6% (1% organically) to $1,425 million, while revenues in the Americas decreased by 2.5% (4.4% organically) to $1,230 million [9][10]. Future Outlook - For 2026, adjusted EPS is projected to be in the range of $8.38-$8.53, indicating growth of 11.1-13.1%, with reported EPS expected between $7.87-$8.02 compared to $7.26 in 2025 [12]. - The company anticipates net revenues to increase by 5-7% on an organic basis and operating income to rise by 7-9% in 2026 [14]. - Management expects an operating cash flow of around $13.5 billion and capital expenditures of $1.4 to $1.6 billion, primarily for smoke-free business investments [14].